Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01ARU
|
|||
Drug Name |
DST-2970
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
Company |
DisperSol Technologies
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Inhibitor | [2] |
BioCyc | Superpathway of steroid hormone biosynthesis | |||
Glucocorticoid biosynthesis | ||||
Androgen biosynthesis | ||||
KEGG Pathway | Steroid hormone biosynthesis | |||
Metabolic pathways | ||||
Ovarian steroidogenesis | ||||
Prolactin signaling pathway | ||||
Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
Steroidogenesis | ||||
Reactome | Androgen biosynthesis | |||
Glucocorticoid biosynthesis | ||||
Endogenous sterols | ||||
WikiPathways | Metapathway biotransformation | |||
Steroid Biosynthesis | ||||
Oxidation by Cytochrome P450 | ||||
Metabolism of steroid hormones and vitamin D | ||||
Glucocorticoid & Mineralcorticoid Metabolism | ||||
Prostate Cancer | ||||
Phase 1 - Functionalization of compounds |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04291664) PK and Dose Escalation and Expansion Study of DST-2970. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of DisperSol Technologies. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.